General

Common Present on Admission Diagnosis

Acidosis	Details
Acute Post-Hemorrhagic Anemia	Details
Acute Renal Failure	Details
Acute Respiratory Failure	Details
Acute Thromboembolism of Deep Veins of Lower Extremities	Details
Anemia	Details
Bacteremia	Details
Bipolar disorder, unspecified	Details
Cardiac Arrest	Details
Cardiac Dysrhythmia	Details
Cardiogenic Shock	Details
Decubitus Ulcer	Details
Dementia in Conditions Classified Elsewhere	Details
Disorder of Liver	Details
Electrolyte and Fluid Disorder	Details
Intestinal Infection due to Clostridium Difficile	Details
Methicillin Resistant Staphylococcus Aureus Infection	Details
Obstructive Chronic Bronchitis with Exacerbation	Details
Other Alteration of Consciousness	Details
Other and Unspecified Coagulation Defects	Details
Other Pulmonary Embolism and Infarction	Details
Phlebitis and Thrombophlebitis	Details
Protein-calorie Malnutrition	Details
Psychosis, unspecified psychosis type	Details
Schizophrenia Disorder	Details
] Sepsis	Details
Septic Shock	Details
Septicemia	Details
] Type II or Unspecified Type Diabetes Mellitus with Mention of Complication, Not Stated as Uncontrolled	Details
Urinary Tract Infection, Site Not Specified	Details

Admission or Observation (Single Response)

() Admit to inpatient

Diagnosis: Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights.

() Admit to IP- University Teaching Service	Diagnosis: Admitting Physician: Resident Physician: Resident team assignment: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgement and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights. To reach the team taking care of this patient please call the University Teaching Service Answering Service at (713) 363-9648 and ask for the team taking care of the patient to be paged. The team name is listed in both "Treatment Teams" and "Notes from Clinical Staff" sections in the Summary\Overview tab of Epic.
() Outpatient observation services under general supervision	Diagnosis: Admitting Physician: Patient Condition: Bed request comments:
() UTS - Outpatient observation services under general supervision	Diagnosis: Admitting Physician: Resident Physician: Resident team assignment: Patient Condition: Bed request comments: To reach the team taking care of this patient please call the University Teaching Service Answering Service at (713) 363-9648 and ask for the team taking care of the patient to be paged. The team name is listed in both "Treatment Teams" and "Notes from Clinical Staff" sections in the Summary\Overview tab of Epic.
() Outpatient in a bed - extended recovery	Diagnosis: Admitting Physician: Bed request comments:
Admission or Observation (Single Response) Patient has active status order on file	
() Admit to inpatient	Diagnosis: Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights.

() Admit to IP- University Teaching Service	Diagnosis: Admitting Physician:
	Resident Physician:
	Resident team assignment:
	Level of Care:
	Patient Condition:
	Bed request comments: Certification: I certify that based on my best clinical judgement
	and the patient's condition as documented in the HP and
	progress notes, I expect that the patient will need hospital
	services for two or more midnights.
	To reach the team taking care of this patient please call the
	University Teaching Service Answering Service at (713)
	363-9648 and ask for the team taking care of the patient to be
	paged. The team name is listed in both "Treatment Teams" and "Notes from Clinical Staff" sections in the
	Summary\Overview tab of Epic.
() Outpatient observation services under general	Diagnosis:
supervision	Admitting Physician:
	Patient Condition:
	Bed request comments:
 UTS - Outpatient observation services under general supervision 	Diagnosis: Admitting Physician:
Supervision	Resident Physician:
	Resident team assignment:
	Patient Condition:
	Bed request comments:
	To reach the team taking care of this patient please call the
	University Teaching Service Answering Service at (713) 363-9648 and ask for the team taking care of the patient to be
	paged. The team name is listed in both "Treatment Teams"
	and "Notes from Clinical Staff" sections in the
	Summary\Overview tab of Epic.
() Outpatient in a bed - extended recovery	Diagnosis:
	Admitting Physician:
	Bed request comments:
Admission (Single Response)	
Patient has active status order on file.	
() Admit to inpatient	Diagnosis:
	Admitting Physician:
	Level of Care:
	Patient Condition:
	Bed request comments:
	Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and
	progress notes, I expect that the patient will need hospital
	services for two or more midnights.
	-
Admission or Observation (Single Response)	
() Admit to inpatient	Diagnosis:
	Admitting Physician: Level of Care:
	Patient Condition:
	Bed request comments:
	Certification: I certify that based on my best clinical judgment
	and the patient's condition as documented in the HP and
	progress notes, I expect that the patient will need hospital
	services for two or more midnights.

() Outpatient observation services under general supervision	Diagnosis: Admitting Physician: Patient Condition: Bed request comments:
() Outpatient in a bed - extended recovery	Diagnosis: Admitting Physician: Bed request comments:
Admission or Observation (Single Response) Patient has status order on file	
() Admit to inpatient	Diagnosis: Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights.
() Outpatient observation services under general supervision	Diagnosis: Admitting Physician: Patient Condition: Bed request comments:
() Outpatient in a bed - extended recovery	Diagnosis: Admitting Physician: Bed request comments:
Code Status	
[] Full code	Code Status decision reached by:
[] DNR	
[] DNR (Do Not Resuscitate)	Does patient have decision-making capacity?
[] Consult to Palliative Care Service	Priority: Reason for Consult? Order?
	Name of referring provider:
	Enter call back number:
[] Consult to Social Work [] Modified Code	Reason for Consult: Does patient have decision-making capacity?
	Modified Code restrictions:
[] Treatment Restrictions	Treatment Restriction decision reached by: Specify Treatment Restrictions:
Isolation	
[] Airborne isolation status	
[] Airborne isolation status	Details
[] Mycobacterium tuberculosis by PCR - If you suspect Tuberculosis, please order this test for rapid diagnostics.	Once, Sputum
[] Contact isolation status	Details
[] Droplet isolation status	Details
[] Enteric isolation status	Details
Precautions	
[] Aspiration precautions	Details
[] Fall precautions	Increased observation level needed:
[] Latex precautions	Details
[] Seizure precautions	Increased observation level needed:
Nureina	

Nursing

Vital signs Printed on 9/16/2019 at 12:45 PM from SUP

X] Vital signs - T/P/R/BP (per unit protocol)	Routine, Per unit protocol
Felemetry Order	
] Telemetry	"And" Linked Panel
[] Telemetry monitoring	Routine, Continuous
	Order: Place in Centralized Telemetry Monitor: EKG
	Monitoring Only (Telemetry Box)
	Reason for telemetry: Chest pain syndrome
	Can be off of Telemetry for tests and baths? Yes
[] Telemetry Additional Setup Information	Routine, Continuous
	High Heart Rate (BPM): 120
	Low Heart Rate(BPM): 50
	High PVC's (per minute): 10
	High SBP(mmHg): 175
	Low SBP(mmHg): 100
	High DBP(mmHg): 95
	Low DBP(mmHg): 40
	Low Mean BP: 60
	High Mean BP: 120
	Low SPO2(%): 94
Activity	
] Up ad lib	Routine, Until discontinued, Starting S
	Specify: Up ad lib
] Strict bed rest	Routine, Until discontinued, Starting S
•	Routine, Until discontinued, Starting S
] Bed rest with bathroom privileges	Bathroom Privileges: with bathroom privileges
	Baunoon Privileges. with baunoon privileges
lursing Care	
] Daily weights	Routine, Daily
] Intake and Output Qshift	Routine, Every shift
] Nasogastric Tube Insert and Maintain	
 [] Nasogastric tube insertion 	Routine, Once
	Туре:
[] Nasogastric tube maintenance	Routine, Until discontinued, Starting S
	Tube Care Orders:
] Insert and Maintain Foley	
[] Insert Foley catheter	Routine, Once
	Туре:
	Size:
	Urinometer needed:
[] Foley Catheter Care	Routine, Until discontinued, Starting S
	Orders: Maintain
	Orders. Maintain
	Orders. Maintain
lotify Physician	
lotify Physician	Routine, Until discontinued, Starting S
otify Physician	Routine, Until discontinued, Starting S Temperature greater than: 100.5
lotify Physician	Routine, Until discontinued, Starting S Temperature greater than: 100.5 Temperature less than:
lotify Physician	Routine, Until discontinued, Starting S Temperature greater than: 100.5 Temperature less than: Systolic BP greater than: 160
lotify Physician	Routine, Until discontinued, Starting S Temperature greater than: 100.5 Temperature less than: Systolic BP greater than: 160 Systolic BP less than: 90
lotify Physician	Routine, Until discontinued, Starting S Temperature greater than: 100.5 Temperature less than: Systolic BP greater than: 160 Systolic BP less than: 90 Diastolic BP greater than: 100
lotify Physician	Routine, Until discontinued, Starting S Temperature greater than: 100.5 Temperature less than: Systolic BP greater than: 160 Systolic BP less than: 90 Diastolic BP greater than: 100 Diastolic BP less than: 50
lotify Physician	Routine, Until discontinued, Starting S Temperature greater than: 100.5 Temperature less than: Systolic BP greater than: 160 Systolic BP less than: 90 Diastolic BP greater than: 100
Iotify Physician X] Notify Physician(vitals,output,pulse ox)	Routine, Until discontinued, Starting S Temperature greater than: 100.5 Temperature less than: Systolic BP greater than: 160 Systolic BP less than: 90 Diastolic BP greater than: 100 Diastolic BP less than: 50
Notify Physician	Routine, Until discontinued, Starting S Temperature greater than: 100.5 Temperature less than: Systolic BP greater than: 160 Systolic BP less than: 90 Diastolic BP greater than: 100 Diastolic BP less than: 50 Heart rate greater than (BPM): 100
Notify Physician	Routine, Until discontinued, Starting S Temperature greater than: 100.5 Temperature less than: Systolic BP greater than: 160 Systolic BP less than: 90 Diastolic BP greater than: 100 Diastolic BP less than: 50 Heart rate greater than (BPM): 100 Heart rate less than (BPM): 60 Respiratory rate greater than: 25
Notify Physician	Routine, Until discontinued, Starting S Temperature greater than: 100.5 Temperature less than: Systolic BP greater than: 160 Systolic BP less than: 90 Diastolic BP greater than: 100 Diastolic BP less than: 50 Heart rate greater than (BPM): 100 Heart rate less than (BPM): 60 Respiratory rate greater than: 25 Respiratory rate less than: 8
lotify Physician	Routine, Until discontinued, Starting S Temperature greater than: 100.5 Temperature less than: Systolic BP greater than: 160 Systolic BP less than: 90 Diastolic BP greater than: 100 Diastolic BP less than: 50 Heart rate greater than (BPM): 100 Heart rate less than (BPM): 60 Respiratory rate greater than: 25 Respiratory rate less than: 8 SpO2 less than: 92
lotify Physician	Routine, Until discontinued, Starting S Temperature greater than: 100.5 Temperature less than: Systolic BP greater than: 160 Systolic BP less than: 90 Diastolic BP greater than: 100 Diastolic BP less than: 50 Heart rate greater than (BPM): 100 Heart rate less than (BPM): 60 Respiratory rate greater than: 25 Respiratory rate less than: 8

Notify Physician- UTS	
[] Notify Physician- Teaching Service	Routine, Until discontinued, Starting S, To reach the team taking care of this patient please call the University Teaching Service Answering Service at (713) 363-9648 and ask for the team taking care of the patient to be paged.
	The team name is listed in both "Treatment Teams" and "Notes from Clinical Staff" sections in the Summary\Overview tab of Epic. If no response, page the Sr. Resident at 713- 768-0403. If no response is obtained using second pager, page the attending assigned to the patient.
Diet (Single Response)	
() NPO	Diet effective now, Starting S NPO: Pre-Operative fasting options:
() Diet	Diet effective now, Starting S Diet(s): Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction: Foods to Avoid:
Tube Feed	
[] Tube feeding - Continuous	Continuous Tube Feeding Formula: Tube Feeding Schedule: Continuous Tube Feeding Route: Initial Tube Feed rate (mL/hr): Advance Rate by (mL/hr): Goal Tube Feed Rate (mL/hr): Dietitian to manage Tube Feed?
[] Tube feeding - Bolus	Diet effective now, Starting S Tube Feeding Formula: Tube Feeding Schedule: Bolus Bolus Route: Tube Feeding Bolus (mL): Additional Bolus Schedule Instructions: Dietitian to manage Tube Feed?

] Tube feeding - Cyclic	Cyclic
	Tube Feeding Formula:
	Tube Feeding Formula: Tube Feeding Schedule: Cyclic
	Tube Feeding Route:
	Tube Feeding Cyclic (start / stop time):
	Tube Feeding Cyclic Rate (mL/hr):
	Dietitian to manage Tube Feed?
IV Fluids	
Peripheral IV Access	
[X] Initiate and maintain IV	
[X] Insert peripheral IV	Routine, Once
[X] sodium chloride 0.9 % flush	10 mL, intravenous, every 12 hours scheduled
[X] sodium chloride 0.9 % flush	10 mL, intravenous, PRN, line care
V Bolus (Single Response)	
() sodium chloride 0.9 % bolus 500 mL	500 mL, intravenous, for 15 Minutes, once, For 1 Doses
) sodium chloride 0.9 % bolus 1000 mL	1,000 mL, intravenous, for 30 Minutes, once, For 1 Doses
) lactated ringer's bolus 500 mL	500 mL, intravenous, for 15 Minutes, once, For 1 Doses
() lactated ringers bolus 1000 mL	1,000 mL, intravenous, for 30 Minutes, once, For 1 Doses
Maintenance IV Fluids (Single Response)	
() sodium chloride 0.9 % infusion	75 mL/hr, intravenous, continuous
() lactated Ringer's infusion	75 mL/hr, intravenous, continuous
() dextrose 5 % and sodium chloride 0.45 % with	75 mL/hr, intravenous, continuous
potassium chloride 20 mEq/L infusion	75 ml/hr introveneue continueue
() sodium chloride 0.45 % infusion	75 mL/hr, intravenous, continuous
 sodium chloride 0.45 % 1,000 mL with sodium bicarbonate 75 mEq/L infusion 	75 mL/hr, intravenous, continuous
Medications	
For Analgesics, please refer to the General Pain Manage	gement order sets.
For Antihypertensives, please refer to the Hypertensive	
Antibiotics	
] azithromycin (ZITHROMAX) IV	intravenous, for 60 Minutes
	Reason for Therapy:
] azithromycin (ZITHROMAX) tablet	oral, daily
	Reason for Therapy:
] cefepime (MAXIPIME) IV	intravenous
	Reason for Therapy:
] ceftriaxone (ROCEPHIN) IV	intravenous, for 30 Minutes
	Reason for Therapy:
] ciprofloxacin (CIPRO) IV	intravenous, for 60 Minutes
	Reason for Therapy:
] ciprofloxacin (CIPRO) tablet	100 mg, oral, 2 times daily
] levofloxacin (LEVAQUIN) IV	intravenous
	Reason for Therapy:
[] levofloxacin (LEVAQUIN) tablet	oral, daily at 0600 (time critical)
	Reason for Therapy:

Reason for Therapy:

Reason for Therapy:

intravenous

Printed on 9/16/2019 at 12:45 PM from SUP

[] meropenem (MERREM) IV

[] metroNIDAZOLE (FLAGYL) IV	intravenous Reason for Therapy:
] metroNIDAZOLE (FLAGYL) tablet	500 mg, oral, 3 times daily Reason for Therapy:
] piperacillin-tazobactam (ZOSYN) IV	intravenous Reason for Therapy:
] vancomycin (VANCOCIN) IV	intravenous Type of Therapy:
Shortness of Breath	
] albuterol (PROVENTIL) nebulizer solution	2.5 mg, nebulization, Respiratory Therapy - every 4 hours Aerosol Delivery Device:
] albuterol (PROVENTIL) nebulizer solution	2.5 mg, nebulization, every 4 hours PRN, shortness of breath Aerosol Delivery Device:
] ipratropium (ATROVENT) 0.02 % nebulizer solution	0.5 mg, nebulization, Respiratory Therapy - every 4 hours Aerosol Delivery Device:
] ipratropium (ATROVENT) 0.02 % nebulizer solution	0.5 mg, nebulization, every 4 hours PRN, shortness of breath Aerosol Delivery Device:
Cough (Single Response)	
) guaiFENesin (MUCINEX) 12 hr tablet	600 mg, oral, 2 times daily PRN, cough
 dextromethorphan-guaifenesin (MUCINEX DM REGULAR) 30-600 mg per 12 hr tablet 	1 tablet, oral, every 12 hours PRN, cough
() guaiFENesin (ROBITUSSIN) 100 mg/5 mL syrup	100 mg, oral, every 4 hours PRN, cough
) dextromethorphan-guaifenesin (ROBITUSSIN-DM) 10-100 mg/5 mL liquid	5 mL, oral, every 4 hours PRN, cough
) codeine-guaifenesin (GUAIFENESIN AC) 10-100 mg/5 mL liquid	5 mL, oral, every 4 hours PRN, cough
() benzonatate (TESSALON) capsule	100 mg, oral, every 6 hours PRN, cough
Constipation - NOT HMSJ	
] docusate sodium (COLACE) capsule	100 mg, oral, 2 times daily PRN, constipation
] senna (SENOKOT) tablet	1 tablet, oral, 2 times daily PRN, constipation, stool softening
] sennosides-docusate sodium (SENOKOT-S) 8.6-50 mg per tablet	1 tablet, oral, daily PRN, constipation
] polyethylene glycol (MIRALAX) packet	17 g, oral, daily PRN, constipation
] magnesium hydroxide suspension	30 mL, oral, daily PRN, constipation
] psyllium (METAMUCIL) 3.4 gram packet] bisacodyl (DULCOLAX) suppository	1 packet, oral, daily PRN, constipation 10 mg, rectal, daily PRN, constipation
Constipation - HMSJ Only	
] docusate sodium (COLACE) capsule	100 mg, oral, 2 times daily PRN, constipation
] sennosides-docusate sodium (SENOKOT-S) 8.6-50 mg per tablet 	1 tablet, oral, daily PRN, constipation
] polyethylene glycol (MIRALAX) packet	17 g, oral, daily PRN, constipation
] magnesium hydroxide suspension	30 mL, oral, daily PRN, constipation
] psyllium (METAMUCIL) 3.4 gram packet	1 packet, oral, daily PRN, constipation
] bisacodyl (DULCOLAX) suppository	10 mg, rectal, daily PRN, constipation
nsomnia: For Patients LESS than 70 years old (Single Res	
() zolpidem (AMBIEN) tablet	5 mg, oral, nightly PRN, sleep
() ramelteon (ROZEREM) tablet	8 mg, oral, nightly PRN, sleep
nsomnia: For Patients GREATER than or EQUAL to 70 year	
() ramelteon (ROZEREM) tablet	8 mg, oral, nightly PRN, sleep
Antiemetics	
[X] ondansetron (ZOFRAN) IV or Oral	"Or" Linked Panel

4 mg, oral, every 8 hours PRN, nausea, vomiting Give if patient is able to tolerate oral medication.
Give il patierit is able to tolerate oral medication.
4 mg, intravenous, every 8 hours PRN, nausea, vomiting Give if patient is UNable to tolerate oral medication OR if a
faster onset of action is required.
"Or" Linked Panel
12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required.
12.5 mg, oral, every 6 hours PRN, nausea, vomiting Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication.
12.5 mg, rectal, every 6 hours PRN, nausea, vomiting Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication.
ponse)
5 mg, oral, daily PRN, itching
se)
25 mg, oral, every 6 hours PRN, itching
10 mg, oral, every 6 hours PRN, itching
5 mg, oral, daily PRN, itching
60 mg, oral, 2 times daily PRN, itching
"Or" Linked Panel
20 mg, intravenous, 2 times daily IV or ORAL
20 mg, oral, 2 times daily IV or ORAL
IV or ORAL
IV or ORAL "Or" Linked Panel 40 mg, oral, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: 40 mg, intravenous, daily at 0600
IV or ORAL "Or" Linked Panel 40 mg, oral, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: 40 mg, intravenous, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: oral, daily
IV or ORAL "Or" Linked Panel 40 mg, oral, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: 40 mg, intravenous, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: oral, daily Indication(s) for Proton Pump Inhibitor (PPI) Therapy:
IV or ORAL "Or" Linked Panel 40 mg, oral, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: 40 mg, intravenous, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: oral, daily
IV or ORAL "Or" Linked Panel 40 mg, oral, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: 40 mg, intravenous, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: oral, daily Indication(s) for Proton Pump Inhibitor (PPI) Therapy: "Or" Linked Panel
IV or ORAL "Or" Linked Panel 40 mg, oral, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: 40 mg, intravenous, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: oral, daily Indication(s) for Proton Pump Inhibitor (PPI) Therapy: "Or" Linked Panel 1 g, oral, 4 times daily with meals and nightly Use with Nasogastric tubing. Use if patient is unable to
IV or ORAL "Or" Linked Panel 40 mg, oral, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: 40 mg, intravenous, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: oral, daily Indication(s) for Proton Pump Inhibitor (PPI) Therapy: "Or" Linked Panel 1 g, oral, 4 times daily with meals and nightly Use with Nasogastric tubing. Use if patient is unable to swallow tablet. 30 mL, oral, every 4 hours PRN, indigestion Do not give if patient is on hemodialysis or in chronic renal
IV or ORAL "Or" Linked Panel 40 mg, oral, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: 40 mg, intravenous, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: oral, daily Indication(s) for Proton Pump Inhibitor (PPI) Therapy: "Or" Linked Panel 1 g, oral, 4 times daily with meals and nightly Use with Nasogastric tubing. Use if patient is unable to swallow tablet. 30 mL, oral, every 4 hours PRN, indigestion Do not give if patient is on hemodialysis or in chronic renal failure.
IV or ORAL "Or" Linked Panel 40 mg, oral, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: 40 mg, intravenous, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: oral, daily Indication(s) for Proton Pump Inhibitor (PPI) Therapy: "Or" Linked Panel 1 g, oral, 4 times daily with meals and nightly Use with Nasogastric tubing. Use if patient is unable to swallow tablet. 30 mL, oral, every 4 hours PRN, indigestion Do not give if patient is on hemodialysis or in chronic renal
IV or ORAL "Or" Linked Panel 40 mg, oral, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: 40 mg, intravenous, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: oral, daily Indication(s) for Proton Pump Inhibitor (PPI) Therapy: "Or" Linked Panel 1 g, oral, 4 times daily with meals and nightly Use with Nasogastric tubing. Use if patient is unable to swallow tablet. 30 mL, oral, every 4 hours PRN, indigestion Do not give if patient is on hemodialysis or in chronic renal failure. 80 mg, oral, every 4 hours PRN, flatulence, For 2 Doses
IV or ORAL "Or" Linked Panel 40 mg, oral, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: 40 mg, intravenous, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: oral, daily Indication(s) for Proton Pump Inhibitor (PPI) Therapy: "Or" Linked Panel 1 g, oral, 4 times daily with meals and nightly Use with Nasogastric tubing. Use if patient is unable to swallow tablet. 30 mL, oral, every 4 hours PRN, indigestion Do not give if patient is on hemodialysis or in chronic renal failure. 80 mg, oral, every 4 hours PRN, flatulence, For 2 Doses "Or" Linked Panel
IV or ORAL "Or" Linked Panel 40 mg, oral, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: 40 mg, intravenous, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: oral, daily Indication(s) for Proton Pump Inhibitor (PPI) Therapy: "Or" Linked Panel 1 g, oral, 4 times daily with meals and nightly Use with Nasogastric tubing. Use if patient is unable to swallow tablet. 30 mL, oral, every 4 hours PRN, indigestion Do not give if patient is on hemodialysis or in chronic renal failure. 80 mg, oral, every 4 hours PRN, flatulence, For 2 Doses "Or" Linked Panel 20 mg, intravenous, 2 times daily IV or ORAL
IV or ORAL "Or" Linked Panel 40 mg, oral, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: 40 mg, intravenous, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: oral, daily Indication(s) for Proton Pump Inhibitor (PPI) Therapy: "Or" Linked Panel 1 g, oral, 4 times daily with meals and nightly Use with Nasogastric tubing. Use if patient is unable to swallow tablet. 30 mL, oral, every 4 hours PRN, indigestion Do not give if patient is on hemodialysis or in chronic renal failure. 80 mg, oral, every 4 hours PRN, flatulence, For 2 Doses "Or" Linked Panel 20 mg, intravenous, 2 times daily

[] pantoprazole (PROTONIX) EC tablet	40 mg, oral, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy:
[] pantoprazole (PROTONIX) 40 mg in sodium chloride 0.9	40 mg, intravenous, daily at 0600
% 10 mL injection	Indication(s) for Proton Pump Inhibitor (PPI) Therapy:
	"Or" Linked Panel
[] sucralfate (CARAFATE) tablet - NOT RECOMMENDED	1 g, oral, 4 times daily with meals and nightly
FOR CHRONIC KIDNEY DISEASE STAGE 3 OR GREATER	
[] sucralfate (CARAFATE) 100 mg/mL suspension - NOT RECOMMENDED FOR CHRONIC KIDNEY DISEASE STAGE 3 OR GREATER	1 g, Nasogastric, 4 times daily with meals and nightly Use with Nasogastric tubing. Use if patient is unable to swallow tablet.
alum-mag hydroxide-simeth (MAALOX) 200-200-20	30 mL, oral, every 4 hours PRN, indigestion
	Do not give if patient is on hemodialysis or in chronic renal failure.
	80 mg, oral, every 4 hours PRN, flatulence, For 2 Doses
TE	
VT Risk and Prophylaxis Tool (Single Response) Low Risk Definition Moderate Risk Definition	
Pharmacologic prophylaxis must be addressed. Mechanical pro contraindicated. High Risk Definition	ophylaxis is optional unless pharmacologic is
Both pharmacologic AND mechanical prophylaxis must be addr	ressed.
Age less than 60 years and NO other VTE risk factors One or rr following medical conditions:	
Patient already adequately anticoagulated CHF, MI, lung diseas	se, pneumonia, active inflammation, dehydration, varicose
veins, cancer, sepsis, obesity, previous stroke, rheumatologic d	
stasis and nephrotic syndrome Thrombophilia (Factor V Leiden	
syndrome; antithrombin, protein C or protein S deficiency; hype	erhomocysteinemia; myeloproliferative disorders)
syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg	erhomocysteinemia; myeloproliferative disorders)
syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis	
syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas	3
syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina	s I or pelvic surgery for CANCER
syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemics	s I or pelvic surgery for CANCER
syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemic s Estrogen therapy History of PE	s I or pelvic surgery for CANCER
syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemic s Estrogen therapy History of PE Moderate or major surgery (not for cancer)	s I or pelvic surgery for CANCER
syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemic s Estrogen therapy History of PE	s I or pelvic surgery for CANCER
syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemic s Estrogen therapy History of PE Moderate or major surgery (not for cancer) Major surgery within 3 months of admission	s I or pelvic surgery for CANCER
syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemic s Estrogen therapy History of PE Moderate or major surgery (not for cancer) Major surgery within 3 months of admission	s I or pelvic surgery for CANCER
syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemic s Estrogen therapy History of PE Moderate or major surgery (not for cancer) Major surgery within 3 months of admission	s I or pelvic surgery for CANCER stroke
syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemic s Estrogen therapy History of PE Moderate or major surgery (not for cancer) Major surgery within 3 months of admission	s Il or pelvic surgery for CANCER stroke Routine, Once
syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemic s Estrogen therapy History of PE Moderate or major surgery (not for cancer) Major surgery within 3 months of admission	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed.
syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemic s Estrogen therapy History of PE Moderate or major surgery (not for cancer) Major surgery within 3 months of admission	s Il or pelvic surgery for CANCER stroke Routine, Once
syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemic s Estrogen therapy History of PE Moderate or major surgery (not for cancer) Major surgery within 3 months of admission	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation
syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemic s Estrogen therapy History of PE Moderate or major surgery (not for cancer) Major surgery within 3 months of admission	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation
syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemic s Estrogen therapy History of PE Moderate or major surgery (not for cancer) Major surgery within 3 months of admission Low Risk of DVT [] Low Risk (Single Response) () Low risk of VTE Moderate Risk of DVT - Surgical Address pharmacologic prophylaxis by selecting one of the fol pharmacologic prophylaxis is contraindicated.	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation
syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemic s Estrogen therapy History of PE Moderate or major surgery (not for cancer) Major surgery within 3 months of admission Low Risk of DVT [] Low Risk (Single Response) () Low risk of VTE Moderate Risk of DVT - Surgical Address pharmacologic prophylaxis by selecting one of the fol pharmacologic prophylaxis is contraindicated. [] Moderate Risk [] Moderate Risk of VTE	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation
 syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemic s Estrogen therapy History of PE Moderate or major surgery (not for cancer) Major surgery within 3 months of admission Low Risk of DVT [] Low Risk (Single Response) () Low risk of VTE 	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation
 syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemic s Estrogen therapy History of PE Moderate or major surgery (not for cancer) Major surgery within 3 months of admission Low Risk of DVT Low Risk of DVT Low Risk (Single Response) Low risk of VTE Moderate Risk of DVT - Surgical Address pharmacologic prophylaxis by selecting one of the fol pharmacologic prophylaxis is contraindicated. Moderate Risk Pharmacological Prophylaxis - Surgical 	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation Ilowing. Mechanical prophylaxis is optional unless Routine, Once Routine, Once
 syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemic s Estrogen therapy History of PE Moderate or major surgery (not for cancer) Major surgery within 3 months of admission Low Risk of DVT [] Low Risk (Single Response) () Low risk of VTE 	Routine, Once Ilowing. Mechanical prophylaxis is optional unless Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is
 syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemic s Estrogen therapy History of PE Moderate or major surgery (not for cancer) Major surgery within 3 months of admission Low Risk of DVT [] Low Risk (Single Response) () Low risk of VTE 	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation llowing. Mechanical prophylaxis is optional unless Routine, Once Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indicatior
 syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemic s Estrogen therapy History of PE Moderate or major surgery (not for cancer) Major surgery within 3 months of admission Low Risk of DVT [] Low Risk (Single Response) () Low risk of VTE 	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation llowing. Mechanical prophylaxis is optional unless Routine, Once Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indicatior Therapy for the following:
 syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemic s Estrogen therapy History of PE Moderate or major surgery (not for cancer) Major surgery within 3 months of admission Low Risk of DVT [] Low Risk (Single Response) () Low risk of VTE 	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation llowing. Mechanical prophylaxis is optional unless Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indicatior Therapy for the following: Routine, Once
 syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemic s Estrogen therapy History of PE Moderate or major surgery (not for cancer) Major surgery within 3 months of admission Low Risk of DVT [] Low Risk (Single Response) () Low risk of VTE 	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation llowing. Mechanical prophylaxis is optional unless Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indicatior Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following
 syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemic sets Estrogen therapy History of PE Moderate or major surgery (not for cancer) Major surgery within 3 months of admission Low Risk of DVT Low Risk of DVT Low Risk (Single Response) Low risk of VTE Moderate Risk of DVT - Surgical Address pharmacologic prophylaxis by selecting one of the fol pharmacologic prophylaxis is contraindicated. Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis 	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation llowing. Mechanical prophylaxis is optional unless Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indicatior Therapy for the following: Routine, Once
 syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemic sets togen therapy History of PE Moderate or major surgery (not for cancer) Major surgery within 3 months of admission Low Risk of DVT Low Risk of DVT Low Risk (Single Response) Low risk of VTE Moderate Risk of DVT - Surgical Address pharmacologic prophylaxis by selecting one of the fol pharmacologic prophylaxis is contraindicated. Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) Patient (Single Response) Contraindications exist for pharmacologic prophylaxis 	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation No Mechanical prophylaxis is optional unless Routine, Once Routine, Once Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
 syndrome; antithrombin, protein C or protein S deficiency; hype Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdomina Less than fully and independently ambulatory Acute ischemic sets Estrogen therapy History of PE Moderate or major surgery (not for cancer) Major surgery within 3 months of admission Low Risk of DVT Low Risk of DVT Low Risk (Single Response) Low risk of VTE Moderate Risk of DVT - Surgical Address pharmacologic prophylaxis by selecting one of the fol pharmacologic prophylaxis is contraindicated. Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis 	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation llowing. Mechanical prophylaxis is optional unless Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following

()		
	enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600 (time critical), Startin S+1 For Patients with CrCL LESS than 30 mL/min
()	enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCI GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
()	enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCI GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patient weight of 140 kg or GREATER and CrCl
()	fondaparinux (ARIXTRA) injection	GREATER than 30 mL/min 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT orde this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCI LESS than 30 mL/min. This patient has a history of or suspected case of
()	heparin (porcine) injection	Heparin-Induced Thrombocytopenia (HIT): 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
()	heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
()	warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
()	Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
] N	lechanical Prophylaxis (Single Response)	
()	Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following
• • •	Place/Maintain sequential compression device continuous	contraindication(s): Routine, Continuous
		contraindication(s):
Moc	continuous	contraindication(s): Routine, Continuous
Moc Add pha	continuous derate Risk of DVT - Non-Surgical Iress pharmacologic prophylaxis by selecting one of the follo rmacologic prophylaxis is contraindicated. //oderate Risk	contraindication(s): Routine, Continuous owing. Mechanical prophylaxis is optional unless
Moc Add pha	continuous derate Risk of DVT - Non-Surgical lress pharmacologic prophylaxis by selecting one of the follo rmacologic prophylaxis is contraindicated. Moderate Risk Moderate risk of VTE	contraindication(s): Routine, Continuous
Moc Add pha [] N [] N	continuous derate Risk of DVT - Non-Surgical Iress pharmacologic prophylaxis by selecting one of the follo rmacologic prophylaxis is contraindicated. Moderate Risk Moderate risk of VTE Moderate Risk Pharmacological Prophylaxis -	contraindication(s): Routine, Continuous owing. Mechanical prophylaxis is optional unless
Moc Add pha [] M [] M [] M	continuous derate Risk of DVT - Non-Surgical lress pharmacologic prophylaxis by selecting one of the follo rmacologic prophylaxis is contraindicated. Moderate Risk Moderate risk of VTE	contraindication(s): Routine, Continuous owing. Mechanical prophylaxis is optional unless Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is
Moc Add pha [] M [] [] N ()	continuous derate Risk of DVT - Non-Surgical lress pharmacologic prophylaxis by selecting one of the follo rmacologic prophylaxis is contraindicated. Moderate Risk Moderate risk of VTE Moderate Risk Pharmacological Prophylaxis - Ion-Surgical Patient (Single Response)	contraindication(s): Routine, Continuous owing. Mechanical prophylaxis is optional unless owing. Mechanical prophylaxis is optional unless Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication
Moc Add pha [] M [] [] N ()	continuous derate Risk of DVT - Non-Surgical Iress pharmacologic prophylaxis by selecting one of the follo rmacologic prophylaxis is contraindicated. Moderate Risk Moderate risk of VTE Moderate Risk Pharmacological Prophylaxis - Ion-Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation	contraindication(s): Routine, Continuous wing. Mechanical prophylaxis is optional unless wing. Mechanical prophylaxis is optional unless Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following
Moc Add pha [] M [] [] N ()	continuous derate Risk of DVT - Non-Surgical lress pharmacologic prophylaxis by selecting one of the follor rmacologic prophylaxis is contraindicated. Moderate Risk Moderate Risk Pharmacological Prophylaxis - Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation	contraindication(s): Routine, Continuous owing. Mechanical prophylaxis is optional unless Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
Moc Add pha [] M [] [] N ()	continuous derate Risk of DVT - Non-Surgical lress pharmacologic prophylaxis by selecting one of the follor rmacologic prophylaxis is contraindicated. Moderate Risk Moderate Risk Pharmacological Prophylaxis - Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis enoxaparin (LOVENOX) injection (Single Response)	contraindication(s): Routine, Continuous wing. Mechanical prophylaxis is optional unless Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 40 mg, subcutaneous, daily at 1700 (time critical), Startin S 30 mg, subcutaneous, daily at 1700 (time critical), Startin S For Patients with CrCL LESS than 30 mL/min
Moc Add pha [] M [] [] N ()	continuous derate Risk of DVT - Non-Surgical lress pharmacologic prophylaxis by selecting one of the follor rmacologic prophylaxis is contraindicated. Moderate Risk Moderate Risk Pharmacological Prophylaxis - lon-Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe enoxaparin (LOVENOX) syringe - For Patients with CrCL	contraindication(s): Routine, Continuous owing. Mechanical prophylaxis is optional unless Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 40 mg, subcutaneous, daily at 1700 (time critical), Startir S 30 mg, subcutaneous, daily at 1700 (time critical), Startir S

() fondaparinux (ARIXTRA) injection	 2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCI LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
() heparin (porcine) injection (Recommended for patients	5,000 Units, subcutaneous, every 12 hours
with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical) Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
() Place/Maintain sequential compression device continuous	Routine, Continuous
High Risk of DVT - Surgical	
Address both pharmacologic and mechanical prophylaxis by orc	dering from Pharmacological and Mechanical Prophylaxis.
[] High Risk	
[] High risk of VTE	Routine, Once
[] High Risk Pharmacological Prophylaxis - Surgical Patient	
(Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
	No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.
 Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis 	No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following
() Patient is currently receiving therapeutic anticoagulation	No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following
 () Patient is currently receiving therapeutic anticoagulation () Contraindications exist for pharmacologic prophylaxis () enoxaparin (LOVENOX) injection (Single Response) 	No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 40 mg, subcutaneous, daily at 0600 (time critical), Starting
 () Patient is currently receiving therapeutic anticoagulation () Contraindications exist for pharmacologic prophylaxis () enoxaparin (LOVENOX) injection (Single Response) () enoxaparin (LOVENOX) syringe () enoxaparin (LOVENOX) syringe - For Patients with CrCL 	No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
 () Patient is currently receiving therapeutic anticoagulation () Contraindications exist for pharmacologic prophylaxis () enoxaparin (LOVENOX) injection (Single Response) () enoxaparin (LOVENOX) syringe () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 	No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl
 () Patient is currently receiving therapeutic anticoagulation () Contraindications exist for pharmacologic prophylaxis () enoxaparin (LOVENOX) injection (Single Response) () enoxaparin (LOVENOX) syringe () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min 	No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of
 () Patient is currently receiving therapeutic anticoagulation () Contraindications exist for pharmacologic prophylaxis () enoxaparin (LOVENOX) injection (Single Response) () enoxaparin (LOVENOX) syringe () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min 	No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.

() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g.
() warfarin (COUMADIN) tablet	weight LESS than 50kg and age GREATER than 75yrs. oral, daily at 1700 (time critical), Starting S+1
	Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once
	No mechanical VTE prophylaxis due to the following contraindication(s):
() Place/Maintain sequential compression device continuous	Routine, Continuous
High Risk of DVT - Non-Surgical	
Address both pharmacologic and mechanical prophylaxis by or	dering from Pharmacological and Mechanical Prophylaxis.
] High Risk	
Image: Thigh Risk Image	Routine, Once
] High Risk Pharmacological Prophylaxis - Non-Surgical	
Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once
	No pharmacologic VTE prophylaxis because: patient is
	already on therapeutic anticoagulation for other indication
	Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once
	No pharmacologic VTE prophylaxis due to the following
() enoxaparin (LOVENOX) injection (Single Response)	contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	40 mg, subcutaneous, daily at 1700 (time critical), Startir
() choxapanin (EOVENOX) synnge	S
() enoxaparin (LOVENOX) syringe - For Patients with CrCL	30 mg, subcutaneous, daily at 1700 (time critical), Startir
LESS than 30 mL/min	
	For Patients with CrCL LESS than 30 mL/min
 enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl
mL/min	GREATER than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight	40 mg, subcutaneous, 2 times daily, Starting S
140 kg or GREATER and CrCl GREATER than 30	For Patients weight 140 kg or GREATER and CrCl
mL/min	GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily
	If the patient does not have a history of or suspected case
	of Heparin-Induced Thrombocytopenia (HIT) do NOT orde
	this medication. Contraindicated in patients LESS than
	50kg, prior to surgery/invasive procedure, or CrCI LESS than 30 mL/min.
	This patient has a history of or suspected case of
	Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
() heparin (porcine) injection (Recommended for patients	5,000 Units, subcutaneous, every 12 hours
with high risk of bleeding, e.g. weight < 50kg and age >	Recommended for patients with high risk of bleeding, e.g.
75yrs)	weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical) Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
] Mechanical Prophylaxis (Single Response)	
	Routine, Once
 () Contraindications exist for mechanical prophylaxis 	No mechanical VTE prophylaxis due to the following

() High Risk of DVT - Surgical (Hip/Knee)

Address both pharmacologic and mechanical prophylaxis by ordering from Pharmacological and Mechanical Prophylaxis.

High Risk High risk of VTE	Routine, Once
High Risk Pharmacological Prophylaxis - Hip or Knee	
(Arthroplasty) Surgical Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() apixaban (ELIQUIS) tablet	2.5 mg, oral, every 12 hours, Starting S+1 Indications:
() aspirin chewable tablet	162 mg, oral, daily, Starting S+1
() aspirin (ECOTRIN) enteric coated tablet	162 mg, oral, daily, Starting S+1
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min.
() enoxaparin (LOVENOX) syringe - For Patients weight	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time
between 100-139 kg and CrCl GREATER than 30 mL/min	critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.
 enoxaparin (LOVENOX) syringe - For Patients weight between 140 kg or GREATER and CrCI GREATER than 30 mL/min 	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCI LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
 () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) 	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() rivaroxaban (XARELTO) tablet for hip or knee arthroplasty planned during this admission	10 mg, oral, daily at 0600 (time critical), Starting S+1 To be Given on Post Op Day 1. Indications:
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
() Place/Maintain sequential compression device continuous	Routine, Continuous

 DVT Risk and Prophylaxis Tool (Single Response) Low Risk Definition Moderate Risk Definition Pharmacologic prophylaxis must be addressed. Mechanical proposed contraindicated. High Risk Definition Both pharmacologic AND mechanical prophylaxis must be addresed age less than 60 years and NO other VTE risk factors One or motifollowing medical conditions: Patient already adequately anticoagulated CHF, MI, lung diseased veins, cancer, sepsis, obesity, previous stroke, rheumatologic disstasis and nephrotic syndrome Thrombophilia (Factor V Leiden, psyndrome; antithrombin, protein C or protein S deficiency; hyperfage 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdominal of Less than fully and independently ambulatory Acute ischemic st Estrogen therapy History of PE Moderate or major surgery (not for cancer) Major surgery within 3 months of admission 	ssed. bre of the following medical conditions: One or more of the e, pneumonia, active inflammation, dehydration, varicose sease, sickle cell disease, leg swelling, ulcers, venous prothrombin variant mutations, anticardiolipin antibody nomocysteinemia; myeloproliferative disorders)
() Low Risk of DVT	
[] Low Risk (Single Response)	
() Low risk of VTE	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation
() Moderate Risk of DVT - Surgical	
Address pharmacologic prophylaxis by selecting one of the follo pharmacologic prophylaxis is contraindicated.	wing. Mechanical prophylaxis is optional unless
[] Moderate Risk	
[] Moderate risk of VTE	Routine, Once
[] Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once
	No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once
	No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min
 enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCI GREATER than 30 mL/min 	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
 enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCI GREATER than 30 mL/min 	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min

()	fondaparinux (ARIXTRA) injection	 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT orde this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCI LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
()	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
()	heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
()	warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
()	Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
Мо	derate Risk of DVT - Non-Surgical	
	dress pharmacologic prophylaxis by selecting one of the follo armacologic prophylaxis is contraindicated.	wing. Mechanical prophylaxis is optional unless
[] [Moderate Risk	
[]	Moderate risk of VTE	Routine, Once
	Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)	
()	Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
()	Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
()	enoxaparin (LOVENOX) injection (Single Response)	
()	enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700 (time critical), Startir S+1
()	enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700 (time critical), Startir S+1 For Patients with CrCL LESS than 30 mL/min
()	enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, every 12 hours at 0900, 2100 (tim critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
()	enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCI GREATER than 30 mL/min	40 mg, subcutaneous, every 12 hours at 0900, 2100 (tim critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
()	fondaparinux (ARIXTRA) injection	 2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT ordethis medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCI LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
()	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
	heparin (porcine) injection (Recommended for patients	5,000 Units, subcutaneous, every 12 hours
<u>``</u>	with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.

() Pharmacy consult to manage warfarin (COUMADIN)

High Risk of DVT - Surgical () Address both pharmacologic and mechanical prophylaxis by ordering from Pharmacological and Mechanical Prophylaxis. [] High Risk [] High risk of VTE Routine, Once [] High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) () Patient is currently receiving therapeutic anticoagulation Routine. Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once () Contraindications exist for pharmacologic prophylaxis No pharmacologic VTE prophylaxis due to the following contraindication(s): () enoxaparin (LOVENOX) injection (Single Response) () enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL 30 mg, subcutaneous, daily at 0600 (time critical), Starting LESS than 30 mL/min S+1 For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time between 100-139 kg and CrCl GREATER than 30 critical), Starting S+1 mL/min For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min enoxaparin (LOVENOX) syringe - For Patients weight 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time () 140 kg or GREATER and CrCl GREATER than 30 critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl mL/min GREATER than 30 mL/min () fondaparinux (ARIXTRA) injection 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCI LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): () heparin (porcine) injection 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > AM Recommended for patients with high risk of bleeding, e.g. 75yrs) weight LESS than 50kg and age GREATER than 75yrs. () warfarin (COUMADIN) tablet oral, daily at 1700 (time critical), Starting S+1 Indication: () Pharmacy consult to manage warfarin (COUMADIN) STAT, Until discontinued, Starting S Indication: High Risk of DVT - Non-Surgical () Address both pharmacologic and mechanical prophylaxis by ordering from Pharmacological and Mechanical Prophylaxis. High Risk [] [] High risk of VTE Routine, Once [] High Risk Pharmacological Prophylaxis - Non-Surgical

() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):

()	enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily, Starting S+1
$\left(\right)$	enoxaparin (LOVENOX) syringe - For Patients with CrCL	30 mg, subcutaneous, daily, Starting S+1
. /	LESS than 30 mL/min	For Patients with CrCL LESS than 30 mL/min
()	enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCI GREATER than 30	30 mg, subcutaneous, every 12 hours at 0900, 2100 (tir critical), Starting S+1
mL/min	For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	
()	enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCI GREATER than 30 mL/min	40 mg, subcutaneous, every 12 hours at 0900, 2100 (tir critical) For Patients weight 140 kg or GREATER and CrCl
		GREATER than 30 mL/min
() 1	fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected cas of Heparin-Induced Thrombocytopenia (HIT) do NOT ord this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCI LESS than 30 mL/min.
		This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
	heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g weight LESS than 50kg and age GREATER than 75yrs.
()	warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical) Indication:
()	Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
	n Risk of DVT - Surgical (Hip/Knee) ress both pharmacologic and mechanical prophylaxis by orc	
Add H	ress both pharmacologic and mechanical prophylaxis by orc	dering from Pharmacological and Mechanical Prophylaxis.
Add H [] H	ress both pharmacologic and mechanical prophylaxis by orc ligh Risk High risk of VTE ligh Risk Pharmacological Prophylaxis - Hip or Knee	
Add H] H (/	ress both pharmacologic and mechanical prophylaxis by orc ligh Risk High risk of VTE	dering from Pharmacological and Mechanical Prophylaxis. Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is
Add 	ress both pharmacologic and mechanical prophylaxis by orc ligh Risk High risk of VTE ligh Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response)	dering from Pharmacological and Mechanical Prophylaxis. Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following
Add H H (/)	ress both pharmacologic and mechanical prophylaxis by ord ligh Risk High risk of VTE ligh Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation	dering from Pharmacological and Mechanical Prophylaxis. Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following: Routine, Once
Add H [] H (/)	ress both pharmacologic and mechanical prophylaxis by ord ligh Risk High risk of VTE ligh Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis	dering from Pharmacological and Mechanical Prophylaxis. Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1
Add H [] H (/ ()) () () () () () () () () () () () ()	ress both pharmacologic and mechanical prophylaxis by ord ligh Risk High risk of VTE ligh Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet	dering from Pharmacological and Mechanical Prophylaxis. Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications:
Add H [] H (/) ()	ress both pharmacologic and mechanical prophylaxis by ord ligh Risk High risk of VTE ligh Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response)	 dering from Pharmacological and Mechanical Prophylaxis. Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1
Add H H (/) ()	ress both pharmacologic and mechanical prophylaxis by ord ligh Risk High risk of VTE ligh Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe	dering from Pharmacological and Mechanical Prophylaxis. Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Start S+1
Add H H (/) ()	ress both pharmacologic and mechanical prophylaxis by ord ligh Risk High risk of VTE ligh Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe	 dering from Pharmacological and Mechanical Prophylaxis. Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Start S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1
Add H H (/ () () ()	ress both pharmacologic and mechanical prophylaxis by ord ligh Risk High risk of VTE ligh Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe	 dering from Pharmacological and Mechanical Prophylaxis. Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Starti S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1
Add] H []] H (/ () () () () () () () () () () () () ()	ress both pharmacologic and mechanical prophylaxis by ord ligh Risk High risk of VTE ligh Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis apixaban (ELIQUIS) tablet aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe enoxaparin (LOVENOX) syringe	dering from Pharmacological and Mechanical Prophylaxis. Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Startis S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Startis S+1

() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCI LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
 heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) 	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() rivaroxaban (XARELTO) tablet for hip or knee arthroplasty planned during this admission	10 mg, oral, daily at 0600 (time critical), Starting S+1 To be Given on Post Op Day 1. Indications:
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
following medical conditions: Patient already adequately anticoagulated CHF, MI, lung diseasive veins, cancer, sepsis, obesity, previous stroke, rheumatologic dis stasis and nephrotic syndrome Thrombophilia (Factor V Leiden, syndrome; antithrombin, protein C or protein S deficiency; hyper Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdominal Less than fully and independently ambulatory Acute ischemic s Estrogen therapy History of PE Moderate or major surgery (not for cancer) Major surgery within 3 months of admission	sease, sickle cell disease, leg swelling, ulcers, venous prothrombin variant mutations, anticardiolipin antibody homocysteinemia; myeloproliferative disorders) or pelvic surgery for CANCER
() Low Risk of DVT	
 [] Low Risk (Single Response) () Low risk of VTE 	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation
 Moderate Risk of DVT - Surgical Address pharmacologic prophylaxis by selecting one of the follo pharmacologic prophylaxis is contraindicated. 	owing. Mechanical prophylaxis is optional unless
[] Moderate Risk	
[] Moderate risk of VTE	Routine, Once
 [] Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) 	,
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:

() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
 enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min 	30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
	For Patients with CrCL LESS than 30 mL/min
 enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min 	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl
	GREATER than 30 mL/min
 enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCI GREATER than 30 mL/min 	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patient weight of 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1
	If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCI LESS than 30 mL/min. This patient has a history of or suspected case of
	Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00
	AM
 heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM
75yrs)	Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
() Place/Maintain sequential compression device continuous	Routine, Continuous
) Moderate Risk of DVT - Non-Surgical	
Address pharmacologic prophylaxis by selecting one of the follo pharmacologic prophylaxis is contraindicated.	owing. Mechanical prophylaxis is optional unless
[] Moderate Risk	
[] Moderate risk of VTE	Routine, Once
 Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response) 	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700 (time critical), Starting S
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700 (time critical), Starting S
	For Patients with CrCL LESS than 30 mL/min
inted on 9/16/2019 at 12:45 PM from SUP	Page 20 of 2

 enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCI GREATER than 30 mL/min 	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
 enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCI GREATER than 30 mL/min 	40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	 2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT ordet this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCI LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
 heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) 	5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical) Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following
	contraindication(s):
() Place/Maintain sequential compression device continuous	Routine, Continuous
continuous	Routine, Continuous
continuous High Risk of DVT - Surgical Address both pharmacologic and mechanical prophylaxis by orc [] High Risk	Routine, Continuous dering from Pharmacological and Mechanical Prophylaxis.
continuous High Risk of DVT - Surgical Address both pharmacologic and mechanical prophylaxis by ord [] High Risk [] High risk of VTE	Routine, Continuous
continuous High Risk of DVT - Surgical Address both pharmacologic and mechanical prophylaxis by ord [] High Risk [] High risk of VTE [] High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)	Routine, Continuous dering from Pharmacological and Mechanical Prophylaxis. Routine, Once
continuous High Risk of DVT - Surgical Address both pharmacologic and mechanical prophylaxis by ord [] High Risk [] High risk of VTE [] High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) () Patient is currently receiving therapeutic anticoagulation	Routine, Continuous dering from Pharmacological and Mechanical Prophylaxis. Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
continuous High Risk of DVT - Surgical Address both pharmacologic and mechanical prophylaxis by ord [] High Risk [] High Risk of VTE [] High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) () Patient is currently receiving therapeutic anticoagulation () Contraindications exist for pharmacologic prophylaxis	Routine, Continuous dering from Pharmacological and Mechanical Prophylaxis. Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.
continuous High Risk of DVT - Surgical Address both pharmacologic and mechanical prophylaxis by ord [] High Risk [] High Risk of VTE [] High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) () Patient is currently receiving therapeutic anticoagulation () Contraindications exist for pharmacologic prophylaxis () enoxaparin (LOVENOX) injection (Single Response)	Routine, Continuous dering from Pharmacological and Mechanical Prophylaxis. Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
continuous High Risk of DVT - Surgical Address both pharmacologic and mechanical prophylaxis by ord [] High Risk [] High Risk of VTE [] High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) () Patient is currently receiving therapeutic anticoagulation () Contraindications exist for pharmacologic prophylaxis	Routine, Continuous dering from Pharmacological and Mechanical Prophylaxis. Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
continuous High Risk of DVT - Surgical Address both pharmacologic and mechanical prophylaxis by ord [] High Risk [] High Risk of VTE [] High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) () Patient is currently receiving therapeutic anticoagulation () Contraindications exist for pharmacologic prophylaxis () enoxaparin (LOVENOX) injection (Single Response)	Routine, Continuous dering from Pharmacological and Mechanical Prophylaxis. Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 40 mg, subcutaneous, daily at 0600 (time critical), Startir S+1
continuous High Risk of DVT - Surgical Address both pharmacologic and mechanical prophylaxis by ord [] High Risk [] High Risk of VTE [] High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) () Patient is currently receiving therapeutic anticoagulation () Contraindications exist for pharmacologic prophylaxis () enoxaparin (LOVENOX) injection (Single Response) () enoxaparin (LOVENOX) syringe () enoxaparin (LOVENOX) syringe	Routine, Continuous dering from Pharmacological and Mechanical Prophylaxis. Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 40 mg, subcutaneous, daily at 0600 (time critical), Startir S+1 30 mg, subcutaneous, daily at 0600 (time critical), Startir S+1

() fondaparinux (ARIXTRA) injection	 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCI LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
 () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) 	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
 Place/Maintain sequential compression device continuous 	Routine, Continuous
High Risk of DVT - Non-Surgical	
Address both pharmacologic and mechanical prophylaxis by or	dering from Pharmacological and Mechanical Prophylaxis.
1 Llich Dick	
[] High Risk [] High risk of VTE	Routine, Once
[] High Risk Pharmacological Prophylaxis - Non-Surgical	Rouille, Once
Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once
	No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700 (time critical), Starting S
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700 (time critical), Starting S
	For Patients with CrCL LESS than 30 mL/min
 enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCI GREATER than 30 mL/min 	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
 enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCI GREATER than 30 mL/min 	40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	 2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCI LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
 heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) 	5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.

() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical) Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
 Place/Maintain sequential compression device continuous 	Routine, Continuous
High Risk of DVT - Surgical (Hip/Knee)	
Address both pharmacologic and mechanical prophylaxis by oro	dering from Pharmacological and Mechanical Prophylaxis.
[] High Risk	
[] High risk of VTE	Routine, Once
[] High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once
	No pharmacologic VTE prophylaxis because: patient is
	already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once
	No pharmacologic VTE prophylaxis due to the following contraindication(s):
() apixaban (ELIQUIS) tablet	2.5 mg, oral, every 12 hours, Starting S+1 Indications:
() aspirin chewable tablet	162 mg, oral, daily, Starting S+1
() aspirin (ECOTRIN) enteric coated tablet	162 mg, oral, daily, Starting S+1
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600 (time critical), Startin S+1
() enoxaparin (LOVENOX) syringe	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600 (time critical), Startin S+1 For Patients with CrCL LESS than 30 mL/min.
() enoxaparin (LOVENOX) syringe - For Patients weight	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time
 enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min 	critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.
() enoxaparin (LOVENOX) syringe - For Patients weight	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1
between 140 kg or GREATER and CrCl GREATER than 30 mL/min	For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCI LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
 heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) 	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() rivaroxaban (XARELTO) tablet for hip or knee arthroplasty planned during this admission	10 mg, oral, daily at 0600 (time critical), Starting S+1 To be Given on Post Op Day 1. Indications:

() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
() Place/Maintain sequential compression device continuous	Routine, Continuous

Labs Today

Hematology/Coagulation Today

[] CBC	Once
[] CBC and differential	Once
[] Prothrombin time with INR	Once
[] Partial thromboplastin time	Once

Chemistry Today

[] Albumin	Once
[] Amylase	Once
[] Basic metabolic panel	Once
[] B-type natriuretic peptide	Once
[] CK total	Once
[] Comprehensive metabolic panel	Once
[] Hemoglobin A1c	Once
[] Hepatic function panel	Once
[] Lactic acid level	Once
[] Lipase	Once
[] Lipid panel	Once
[] Magnesium	Once
[] Phosphorus	Once
[] Prealbumin	Once
[] TSH	Once
[] T4, free	Once
[] Uric acid	Once
[] Urine drugs of abuse screen	Once

Cardiac Enzymes

[]	Troponin I : STAT	STAT For 1 Occurrences
[]	Troponin I : Now and every 6 hours x 2	Now then every 6 hours For 2 Occurrences
[]	Troponin I : Now and every 8 hours x 2	Now then every 8 hours For 2 Occurrences

Microbiology

[] Blood culture x 2	"And" Linked Panel
[] Blood Culture (Aerobic & Anae	obic)Once, BloodCollect before antibiotics given. Blood cultures should be ordered x2, with each set drawn from a different peripheral site. If unable to draw both sets from a peripheral site, please call the lab for assistance; an IV line should NEVER be used.
[] Blood Culture (Aerobic & Anae	obic)Once, BloodCollect before antibiotics given. Blood cultures should be ordered x2, with each set drawn from a different peripheral site. If unable to draw both sets from a peripheral site, please call the lab for assistance; an IV line should NEVER be used.

[]	Urinalysis screen and microscopy, with reflex to culture	Once Specimen Source: Urine Specimen Site:
[]	Sputum culture	Once, Sputum

Labs Tomorrow

Hematology/Coagulation Tomorrow

[] CBC	AM draw For 1 Occurrences
[] CBC with differential	AM draw For 1 Occurrences
[] Prothrombin time with INR	AM draw For 1 Occurrences
[] Partial thromboplastin time	AM draw For 1 Occurrences

Chemistry Tomorrow

[] Albumin	AM draw For 1 Occurrences
[] Amylase	AM draw For 1 Occurrences
[] Basic metabolic panel	AM draw For 1 Occurrences
[] B-type natriuretic peptide	AM draw For 1 Occurrences
[] CK total	AM draw For 1 Occurrences
[] Comprehensive metabolic panel	AM draw For 1 Occurrences
[] Hepatic function panel	AM draw For 1 Occurrences
[] Lactic acid level	AM draw For 1 Occurrences
[] Lipase	AM draw For 1 Occurrences
[] Lipid panel	AM draw For 1 Occurrences
[] Magnesium	AM draw For 1 Occurrences
[] Phosphorus	AM draw For 1 Occurrences
[] Prealbumin	AM draw For 1 Occurrences
[] TSH	AM draw For 1 Occurrences
[] T4, free	AM draw For 1 Occurrences
[] Uric acid	AM draw For 1 Occurrences
[] Urine drugs of abuse screen	Once, Starting S+1

Cardiology

Cardiology

[] Myocardial perfusion stress test	Routine, 1 time imaging Must order Stress Test ECG Only order in conjunction.
[] Cv exercise treadmill stress (no imaging)	Routine, Once
ECG 12 lead - Routine	Routine, Once
	Clinical Indications: Chest Pain
	Interpreting Physician:
[] ECG 12 lead - STAT	STAT, Once
	Clinical Indications: Chest Pain
	Interpreting Physician:
[] Echocardiogram complete w contrast and 3D if needed	Routine, 1 time imaging

Imaging MRI/MRA

[] MRI Brain Wo Contrast	Routine, 1 time imaging For 1
[] MRI Brain W Contrast	Routine, 1 time imaging For 1
[] MRI Brain W Wo Contrast	Routine, 1 time imaging For 1
[] MRA Head Wo Contrast	Routine, 1 time imaging For 1
[] MRA Head W Contrast	Routine, 1 time imaging For 1
[] MRA Head W Wo Contrast	Routine, 1 time imaging For 1
[] MRA Neck Wo Contrast	Routine, 1 time imaging For 1
[] MRA Neck W Contrast	Routine, 1 time imaging For 1
[] MRA Neck W Wo Contrast	Routine, 1 time imaging For 1

СТ

[] CT Head Wo Contrast	Routine, 1 time imaging For 1
[] CT Head W Contrast	Routine, 1 time imaging For 1
[] CT Head W Wo Contrast	Routine, 1 time imaging For 1
[] CT Chest Wo Contrast	Routine, 1 time imaging For 1
[] CT Abdomen W Contrast (Omnipaque)	"And" Linked Panel
For those with iodine allergies, please order the panel with	Readi-Cat (barium sulfate).
[] OT Ab dom on W/ Operational	Deutine Atime inceries For A
[] CT Abdomen W Contrast	Routine, 1 time imaging For 1
[] iohexol (OMNIPAQUE) 300 mg iodine/mL oral solution	30 mL, oral, once
[] CT Abdomen Pelvis WO Contrast (Omnipaque)	"And" Linked Panel
For those with iodine allergies, please order the panel with	Readi-Cal (banum sunale).
[] CT Abdomen Pelvis Wo Contrast	Routine, 1 time imaging For 1
[] iohexol (OMNIPAQUE) 300 mg iodine/mL oral solution	30 mL, oral, once
[] CT Abdomen Pelvis WO Contrast (Readi-Cat)	"And" Linked Panel
Ordered as secondary option for those with iodine allergies	
[] CT Abdomen Pelvis Wo Contrast	Routine, 1 time imaging For 1
[] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w)	450 mL, oral, once in imaging, contrast, For 1 Doses
suspension	
[] CT Pelvis W Contrast (Omnipaque)	"And" Linked Panel
For those with iodine allergies, please order the panel with	Readi-Cat (barium sulfate).
[] CT Pelvis W Contrast	Douting, 1 time imaging For 1
	Routine, 1 time imaging For 1 30 mL, oral, once
[] iohexol (OMNIPAQUE) 300 mg iodine/mL oral solution [] CT Abdomen Pelvis WO Contrast (Omnipaque)	"And" Linked Panel
For those with iodine allergies, please order the panel with	
Tor those with louine allergies, please order the parter with	iveaul-Cat (banulli suilate).
[] CT Abdomen Pelvis Wo Contrast	Routine, 1 time imaging For 1
[] iohexol (OMNIPAQUE) 300 mg iodine/mL oral solution	30 mL, oral, once
[] CT Abdomen Pelvis WO Contrast (Readi-Cat)	"And" Linked Panel
[] CT Abdomen Pelvis WO Contrast (Readi-Cat) Ordered as secondary option for those with iodine allergies	"And" Linked Panel
Ordered as secondary option for those with iodine allergies	"And" Linked Panel
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast	"And" Linked Panel Routine, 1 time imaging For 1
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w)	"And" Linked Panel
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w) suspension	"And" Linked Panel Routine, 1 time imaging For 1 450 mL, oral, once in imaging, contrast, For 1 Doses
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w)	"And" Linked Panel Routine, 1 time imaging For 1
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w) suspension [] CT Sinus Wo Contrast	"And" Linked Panel Routine, 1 time imaging For 1 450 mL, oral, once in imaging, contrast, For 1 Doses
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w) suspension [] CT Sinus Wo Contrast	"And" Linked Panel Routine, 1 time imaging For 1 450 mL, oral, once in imaging, contrast, For 1 Doses Routine, 1 time imaging For 1
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w) suspension [] CT Sinus Wo Contrast X-Ray [] Chest 1 Vw Portable	"And" Linked Panel
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w) suspension [] CT Sinus Wo Contrast X-Ray [] Chest 1 Vw Portable [] Chest 1 Vw Portable	 "And" Linked Panel Routine, 1 time imaging For 1 450 mL, oral, once in imaging, contrast, For 1 Doses Routine, 1 time imaging For 1 Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 Occurrences
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w) suspension [] CT Sinus Wo Contrast X-Ray [] Chest 1 Vw Portable [] Chest 2 Vw	 "And" Linked Panel Routine, 1 time imaging For 1 450 mL, oral, once in imaging, contrast, For 1 Doses Routine, 1 time imaging For 1 Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w) suspension [] CT Sinus Wo Contrast X-Ray [] Chest 1 Vw Portable [] Chest 2 Vw [] Chest 2 Vw	 "And" Linked Panel Routine, 1 time imaging For 1 450 mL, oral, once in imaging, contrast, For 1 Doses Routine, 1 time imaging For 1 Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 STAT, 1 time imaging For 1 STAT, 1 time imaging For 1
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w) suspension [] CT Sinus Wo Contrast X-Ray [] Chest 1 Vw Portable [] Chest 2 Vw [] Chest 2 Vw [] KUB Kidney Ureter Bladder	 "And" Linked Panel Routine, 1 time imaging For 1 450 mL, oral, once in imaging, contrast, For 1 Doses Routine, 1 time imaging For 1 Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 Occurrences
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w) suspension [] CT Sinus Wo Contrast X-Ray [] Chest 1 Vw Portable [] Chest 1 Vw Portable [] Chest 2 Vw [] KUB Kidney Ureter Bladder [] KUB Kidney Ureter Bladder	 "And" Linked Panel Routine, 1 time imaging For 1 450 mL, oral, once in imaging, contrast, For 1 Doses Routine, 1 time imaging For 1 Routine, 1 time imaging For 1 STAT, 1 time imaging For 1
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w) suspension [] CT Sinus Wo Contrast X-Ray [] Chest 1 Vw Portable [] Chest 1 Vw Portable [] Chest 2 Vw [] Chest 2 Vw [] KUB Kidney Ureter Bladder [] KUB Kidney Ureter Bladder [] Abdomen 2 Vw Ap W Upright And/Or Decubitus	 "And" Linked Panel Routine, 1 time imaging For 1 450 mL, oral, once in imaging, contrast, For 1 Doses Routine, 1 time imaging For 1 Routine, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 STAT, 1 time imaging For 1
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w) suspension [] CT Sinus Wo Contrast X-Ray [] Chest 1 Vw Portable [] Chest 2 Vw [] Chest 2 Vw [] KUB Kidney Ureter Bladder [] KUB Kidney Ureter Bladder	 "And" Linked Panel Routine, 1 time imaging For 1 450 mL, oral, once in imaging, contrast, For 1 Doses Routine, 1 time imaging For 1 Routine, 1 time imaging For 1 STAT, 1 time imaging For 1
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w) suspension [] CT Sinus Wo Contrast X-Ray [] Chest 1 Vw Portable [] Chest 1 Vw Portable [] Chest 2 Vw [] Chest 2 Vw [] KUB Kidney Ureter Bladder [] KUB Kidney Ureter Bladder [] Abdomen 2 Vw Ap W Upright And/Or Decubitus	 "And" Linked Panel Routine, 1 time imaging For 1 450 mL, oral, once in imaging, contrast, For 1 Doses Routine, 1 time imaging For 1 Routine, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 STAT, 1 time imaging For 1
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w) suspension [] CT Sinus Wo Contrast X-Ray [] Chest 1 Vw Portable [] Chest 1 Vw Portable [] Chest 2 Vw [] Chest 2 Vw [] KUB Kidney Ureter Bladder [] Abdomen 2 Vw Ap W Upright And/Or Decubitus [] Abdomen 2 Vw Ap W Upright And/Or Decubitus	 "And" Linked Panel Routine, 1 time imaging For 1 450 mL, oral, once in imaging, contrast, For 1 Doses Routine, 1 time imaging For 1 Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 STAT, 1 time imaging For 1
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w) suspension [] CT Sinus Wo Contrast X-Ray [] Chest 1 Vw Portable [] Chest 1 Vw Portable [] Chest 2 Vw [] Chest 2 Vw [] KUB Kidney Ureter Bladder [] Abdomen 2 Vw Ap W Upright And/Or Decubitus [] Abdomen 2 Vw Ap W Upright And/Or Decubitus [] US Abdomen Complete	 "And" Linked Panel Routine, 1 time imaging For 1 450 mL, oral, once in imaging, contrast, For 1 Doses Routine, 1 time imaging For 1 Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 Routine, 1 time imaging For 1 Routine, 1 time imaging For 1 Routine, 1 time imaging For 1
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w) suspension [] CT Sinus Wo Contrast X-Ray [] Chest 1 Vw Portable [] Chest 1 Vw Portable [] Chest 2 Vw [] Chest 2 Vw [] KUB Kidney Ureter Bladder [] Abdomen 2 Vw Ap W Upright And/Or Decubitus [] Abdomen 2 Vw Ap W Upright And/Or Decubitus [] US Abdomen Complete [] US Gallbladder	 "And" Linked Panel Routine, 1 time imaging For 1 450 mL, oral, once in imaging, contrast, For 1 Doses Routine, 1 time imaging For 1 Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 Routine, 1 time imaging For 1 Routine, 1 time imaging For 1 Routine, 1 time imaging For 1
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w) suspension [] CT Sinus Wo Contrast X-Ray [] Chest 1 Vw Portable [] Chest 1 Vw Portable [] Chest 2 Vw [] Chest 2 Vw [] KUB Kidney Ureter Bladder [] Abdomen 2 Vw Ap W Upright And/Or Decubitus [] Abdomen 2 Vw Ap W Upright And/Or Decubitus [] US Abdomen Complete [] US Renal	 "And" Linked Panel Routine, 1 time imaging For 1 450 mL, oral, once in imaging, contrast, For 1 Doses Routine, 1 time imaging For 1 Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 Routine, 1 time imaging For 1
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w) suspension [] CT Sinus Wo Contrast X-Ray [] Chest 1 Vw Portable [] Chest 1 Vw Portable [] Chest 2 Vw [] Chest 2 Vw [] KUB Kidney Ureter Bladder [] Abdomen 2 Vw Ap W Upright And/Or Decubitus [] Abdomen 2 Vw Ap W Upright And/Or Decubitus [] US Abdomen Complete [] US Renal [] US Pelvis Complete	 "And" Linked Panel Routine, 1 time imaging For 1 450 mL, oral, once in imaging, contrast, For 1 Doses Routine, 1 time imaging For 1 Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 STAT, 1 time imaging For 1 STAT, 1 time imaging For 1 Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 Routine, 1 time imaging For 1
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w) suspension [] CT Sinus Wo Contrast X-Ray [] Chest 1 Vw Portable [] Chest 1 Vw Portable [] Chest 2 Vw [] Chest 2 Vw [] KUB Kidney Ureter Bladder [] KUB Kidney Ureter Bladder [] Abdomen 2 Vw Ap W Upright And/Or Decubitus [] US Abdomen Complete [] US Renal [] US Pelvis Complete [] US Pelvic Non Ob Limited	"And" Linked Panel Routine, 1 time imaging For 1 450 mL, oral, once in imaging, contrast, For 1 Doses Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 STAT, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 Routine, 1 time imaging For 1
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w) suspension [] CT Sinus Wo Contrast X-Ray [] Chest 1 Vw Portable [] Chest 1 Vw Portable [] Chest 2 Vw [] Chest 2 Vw [] KUB Kidney Ureter Bladder [] KUB Kidney Ureter Bladder [] Abdomen 2 Vw Ap W Upright And/Or Decubitus [] US Abdomen Complete [] US Renal [] US Pelvis Complete [] US Pelvic Non Ob Limited [] US Pelvic Transvaginal	 "And" Linked Panel Routine, 1 time imaging For 1 450 mL, oral, once in imaging, contrast, For 1 Doses Routine, 1 time imaging For 1 Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 Routine, 1 time imaging For 1
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w) suspension [] CT Sinus Wo Contrast X-Ray [] Chest 1 Vw Portable [] Chest 1 Vw Portable [] Chest 2 Vw [] Chest 2 Vw [] KUB Kidney Ureter Bladder [] KUB Kidney Ureter Bladder [] Abdomen 2 Vw Ap W Upright And/Or Decubitus [] US Abdomen Complete [] US Renal [] US Pelvis Complete [] US Pelvis Complete [] US Pelvic Transvaginal [] Pv carotid duplex	 "And" Linked Panel Routine, 1 time imaging For 1 450 mL, oral, once in imaging, contrast, For 1 Doses Routine, 1 time imaging For 1 Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 STAT, 1 time imaging For 1 Routine, 1 time imaging For 1
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w) suspension [] CT Sinus Wo Contrast X-Ray [] Chest 1 Vw Portable [] Chest 1 Vw Portable [] Chest 2 Vw [] Chest 2 Vw [] KUB Kidney Ureter Bladder [] Abdomen 2 Vw Ap W Upright And/Or Decubitus [] US Abdomen Complete [] US Renal [] US Pelvis Complete [] US Pelvic Transvaginal [] Pv duplex arterial upper extremity	 "And" Linked Panel Routine, 1 time imaging For 1 450 mL, oral, once in imaging, contrast, For 1 Doses Routine, 1 time imaging For 1 Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 STAT, 1 time imaging For 1 STAT, 1 time imaging For 1 Routine, 1 time imaging For 1
Ordered as secondary option for those with iodine allergies [] CT Abdomen Pelvis Wo Contrast [] barium (READI-CAT 2) 2.1 % (w/v), 2.0 % (w/w) suspension [] CT Sinus Wo Contrast X-Ray [] Chest 1 Vw Portable [] Chest 1 Vw Portable [] Chest 2 Vw [] Chest 2 Vw [] KUB Kidney Ureter Bladder [] KUB Kidney Ureter Bladder [] Abdomen 2 Vw Ap W Upright And/Or Decubitus [] US Abdomen Complete [] US Renal [] US Pelvis Complete [] US Pelvis Complete [] US Pelvic Transvaginal [] Pv carotid duplex	 "And" Linked Panel Routine, 1 time imaging For 1 450 mL, oral, once in imaging, contrast, For 1 Doses Routine, 1 time imaging For 1 Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 Occurrences Routine, 1 time imaging For 1 STAT, 1 time imaging For 1 STAT, 1 time imaging For 1 Routine, 1 time imaging For 1

Printed on 9/16/2019 at 12:45 PM from SUP

Respiratory

Respiratory

[] Oxygen therapy - NC 2 Lpm

Routine, Continuous Device 1: Nasal Cannula Rate in liters per minute: 2 lpm Rate in tenths of a liter per minute: O2 %: Titrate to keep O2 Sat Above: 92% Indications for O2 therapy: Hypoxemia Device 2: Device 3: Indications for O2 therapy:

Rehab

Consults

Ph	armacy Consult for Anticoagulation	
[]	Pharmacy consult to manage warfarin (COUMADIN)	Routine, Until discontinued, Starting S Indication:
[]	Pharmacy consult to monitor apixaban (ELIQUIS) therapy	STAT, Until discontinued, Starting S
[]	Pharmacy consult to manage dosing of all oral anticoagulants	Routine, Until discontinued, Starting S Which drug do you need help dosing? Contact Number:
[]	Pharmacy Consult to Manage Heparin STANDARD dose protocol (DVT/PE) - initiation bolus and infusion with titration boluses	STAT, Until discontinued, Starting S Heparin Indication: Specify: Give initial Bolus Monitoring: Anti-Xa
[]	Pharmacy consult to manage Heparin LOW dose protocol (ACS/Stroke/Afib) - initiation bolus and infusion withOUT titration boluses	STAT, Until discontinued, Starting S Heparin Indication: Specify: Monitoring: Anti-Xa
An	cillary Consults	
[]	Consult to Case Management	Consult Reason:
[]	Consult to Social Work	Reason for Consult:
[]	Consult PT eval and treat	Special Instructions:
		Weight Bearing Status:
[]	Consult PT wound care	Special Instructions: Location of Wound?
	Consult OT eval and treat	Special Instructions:
[]	Consult OT eval and treat	Weight Bearing Status:
[]	Consult to Nutrition Services	Reason For Consult?
		Purpose/Topic:
[]	Consult to Spiritual Care	Reason for consult?
n	Consult to Speech Language Pathology	Routine, Once
	1 0 0 0;	Reason for consult:
[]	Consult to Wound Ostomy Care nurse	Reason for consult:
	·	Reason for consult:
		Reason for consult:
		Reason for consult:
		Consult for NPWT:
<u> </u>		Reason for consult:
[]	Consult to Respiratory Therapy	Reason for Consult?

Additional Orders